Survival with Cemiplimab in Recurrent Cervical Cancer

Author:

Tewari Krishnansu S.1,Monk Bradley J.1,Vergote Ignace1,Miller Austin1,de Melo Andreia C.1ORCID,Kim Hee-Seung1,Kim Yong Man1,Lisyanskaya Alla1,Samouëlian Vanessa1,Lorusso Domenica1,Damian Fernanda1,Chang Chih-Long1,Gotovkin Evgeniy A.1,Takahashi Shunji1,Ramone Daniella1,Pikiel Joanna1,Maćkowiak-Matejczyk Beata1,Guerra Alía Eva M.1,Colombo Nicoletta1,Makarova Yulia1,Rischin Danny1,Lheureux Stephanie1,Hasegawa Kosei1,Fujiwara Keiichi1,Li Jingjin1,Jamil Shaheda1,Jankovic Vladimir1,Chen Chieh-I1,Seebach Frank1,Weinreich David M.1,Yancopoulos George D.1,Lowy Israel1,Mathias Melissa1,Fury Matthew G.1,Oaknin Ana1

Affiliation:

1. From the Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, University of California, Irvine, Orange (K.S.T.); the Division of Gynecologic Oncology, Arizona Oncology, University of Arizona, and Creighton University, Phoenix (B.J.M.); the Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, University Hospitals, Katholieke Universiteit Leuven, Leuven, Belgium (I.V.); the Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center,...

Funder

Regeneron Pharmaceuticals

Publisher

Massachusetts Medical Society

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3